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As new technologies develop in biomedical sciences, pockets of 
technical expertise arise in individual scientific Institutions and these in 
turn evolve into centers of excellence for a given technology. These 
centers of excellence tend to be referred to as ‘shared’ or ‘core’ facilities 
and they play a key role in establishing best practice, setting quality 
standards, providing skilled services, advancing technologies and 
through economies of scale, delivering value for money (Meder et al., 
2016; Chang and Grieder, 2016; Hockberger et al., 2018). With the 
generation of human embryonic stem cell (hESC) lines in 1998 (Thom-
son et al., 1998; Ludwig et al., 2018) and their promise as tools for 
development, disease modelling and therapeutic application, a new 
portfolio of cell culture techniques began to be developed and along 
with this, associated technologies. This field required expertise and 
training in a number of areas and soon centers providing training in 
hESC work were established. 
The WiCell Stem Cell Bank was the first center to be set up in 1999. 
They not only distribute hESC lines but also provide characterization 
services and initially offered training for the culture of hPSCs. Subse-
quent to this, a number of similar centers were launched globally. In 
2007 the generation of human induced pluripotent stem cells (hiPSC) 
(Yu et al., 2007; Takahashi et al., 2007) provided yet another branch of 
research and development in this scientific area. As the field grew so did 
the number of core facilities, providing training, services and materials 
to both research and translational scientists. Quality standards were 
established (International Stem Cell Banking Initiative, 2009) and 
common practices were shared between expert centers. A need to 
establish networks of core facilities was identified by groups of plurip-
otent stem cell facility directors and this resulted in the formation of the 
COREdinates and the Pluricore groups. 
1. The COREdinates 
At the June 2009 International Society of Stem Cell Research (ISSCR) 
meeting, Sunita D’Souza at Mount Sinai School of Medicine in New York 
City organized the first meeting for seven to eight Stem Cell Core heads, 
who were mostly from the east coast of the USA, to explore the benefits 
of working together, sharing expertise and being connected. In a sub-
sequent meeting in 2010 at the NIH, Mark Tomishima, then at Memorial 
Sloan Kettering Cancer Center, coined the term “COREdinates” for this 
group (https://www.coredinates.org/). The following years, as the field 
of human pluripotent stem cell blossomed, the number of core facilities 
covering this field increased rapidly and the COREdinates group became 
more structured to accommodate a larger number of members. In 2019, 
the COREdinates group includes 47 core facilities, mostly from the USA 
(33 facilities) and Europe (9 facilities). Every other year, presidency of 
the association is rotated amongst the members of COREdinates. 
The common mission of these core facilities is to facilitate and sup-
port all aspects of human pluripotent stem cell research. Most of the 
facilities have a fee-for-service based model in combination with grant 
and/or institution support. The distribution between grant funded pro-
jects and fee for service varies greatly between the facilities. Some fa-
cilities focus on supporting the researchers from their University only, 
others provide their services to other Academic Institutions as well as for 
profit organizations. Together, these core facilities offer a variety of 
services including iPSC derivation and characterization, banking and 
distribution, gene editing, differentiation and training. Some facilities 
provide space and offer reagents preparation and testing. Other areas of 
expertise include cGMP cell manufacturing, bioengineering, chemical 
screening and laboratory automation. 
One of the goals of the COREdinates is to share common practices 
between the different core facilities. In 2011, an email server list was 
established to facilitate the communication between the COREdinate 
members. This email server list is commonly used to share protocols. 
Since 2016, an annual meeting has taken place in the USA where 
members openly discuss topics related to pluripotent stem cells. In 2018, 
the focus was on gene editing since many core facilities were starting to 
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offer it as a service. The topics covered reagents, standard operating 
procedures, automation and workflows, as well as quality control of the 
targeted clones. These meetings and the email server have been 
extremely valuable for the COREdinate members since each core facility 
has a set of expertise that can be quickly transmitted to the rest of the 
group. 
Another goal of the COREdinate is to disseminate knowledge. Since 
2010, the COREdinates group has organized, once a year, a Focus ses-
sion at the International Society for Stem Cell research (ISSCR) meeting. 
This Focus session provides an opportunity for some of the COREdinates 
members to present their work and/or the services offered by their core 
facility. The presentations cover a wide range of human pluripotent stem 
cell related work, representing the diversity of the COREdinates group. 
Another part of the Focus session is dedicated to a unique topic each 
year. In Los Angeles in 2019, our session focused on Parkinson’s disease 
since the first clinical trial using iPS derived dopaminergic neurons to 
treat patients with Parkinson’s disease had just started in Japan. These 
focus sessions have been well attended (around 400 attendees in Mel-
bourne in 2018) and have received positive feedback. ISCBI (htt 
ps://www.iscbi.org) has also held joint meetings with the COR-
Edinates and these joint meetings have enabled a valuable exchange of 
knowledge and skillsets between these two groups. A few years ago, the 
COREdinates group teamed up with Stembook to publish a collection of 
protocols covering many aspects of pluripotent stem cell research and 
development. Stembook was then inactive for several years but was 
revitalized in 2018 by IOS Press. The COREdinates group is working 
again with Stembook to publish validated protocols. In addition, three of 
the four editors of the Lab Resource section of Stem Cell Research 
Journal belong to the COREdinates group. The lab resource section aims 
to catalogue different types of resources, including induced pluripotent 
stem cells and gene edited lines. Authors are required to adhere to stem 
cell nomenclature rules (Luong et al., 2011; Kurtz et al., 2018) as well as 
strict quality control standards in order to have their resource published 
in Stem Cell Research Journal. 
Many core facilities provide workshops to train the next generation 
of scientists joining the stem cell field. For instance, the UK Stem Cell 
Bank and the HSCI iPS core facility have organized joint reprogramming 
workshop for the past 7 years. These practical trainings should improve 
standardization and good practice in the scientific community. 
Lastly, work that was initiated in the Stem Cell Core at Memorial 
Sloan Kettering Cancer Center headed by Mark Tomishima evolved and 
facilitated the 250 million dollar investment and the creation of Blue 
Rock Company, whose goal is to deliver therapeutic stem cell products 
to the community in the near future. We foresee more and more Cores 
evolving and assisting with the production of various types of stem cell 
based therapeutic products in the future. 
2. PluriCore 
As mentioned previously, achieving a high level of standardization is 
important for the derivation, propagation, differentiation as well as for 
the gene editing of human pluripotent stem cells (PSC). Moreover, 
standardization of materials, processes and the assessment of quality is 
essential for manufacturing human PSCs for clinical application. 
Creating such knowledge infrastructure requires a community effort by 
a network of experts. 
This need has motivated scientists in Germany and Europe to create 
the PluriCore network (http://gscn.org/en/RESOURCES/GermanStemC 
ellCores.aspx), where techniques and protocols are shared and dissem-
inated in the scientific community to ensure the highest standards of 
research using PSCs. The initiative was launched by Micha Drukker 
(Helmholtz Center Munich), Harald Stachelscheid (BIH Stem Cell Core, 
Charite – Universitätsmedizin Berlin) and Sebastian Diecke (BIH Stem 
Cell Core, Max-Delbrück-Centrum for Molekular Medicin) and is sup-
ported by the Berlin Institute of Health (BIH) and the German Stem Cell 
Network (GSCN). 
Currently the network comprises 21 partners from Germany and 
Europe and is expanding on the European level, which will increase the 
impact of the technical harmonization and reproducibility. The associ-
ated partners meet annually to discuss specific topics and techniques 
including reprogramming, differentiation, genome engineering, cell 
characterization and process automation. Furthermore, invited speakers 
from academia and industry inform the stem cell community about 
relevant topics including new technological inventions and equipment, 
optimized quality control measurements and laboratory data manage-
ment solutions (LIMS and Electronic notebooks). Over the past 5 years, 
special emphasis has been placed on how to standardize characteriza-
tion and quality control measurements, in particular the methods for 
testing and ensuring the genomic integrity of reprogrammed and engi-
neered cells as well as analysis of the differentiation potencies of indi-
vidual PSC lines. Another important topic addressed by the group was 
ethics, with a focus on the production of a generalized patient consent 
form and precise documentation with an emphasis on biobanking ini-
tiatives. Working groups within the network were formed to address 
specific topics and to formulate recommendations for the stem cell 
community. As a result, the network produced a generic patient consent 
form that can be used as a general template, as well as a standardized 
material transfer agreement form to facilitate the exchange of cell lines. 
Future goals of the network include the establishment of an induced PSC 
line repository with well characterized lines (including information such 
as differentiation capacity, omics data and donor information) derived 
from healthy donors of different age groups which can serve as reference 
material within the network and beyond. This repository will help 
research groups of different institutes to increase the reproducibility of 
experiments and scientific results. In addition, the network plans to 
establish recommendations to standardize the karyotype stability anal-
ysis of PSCs in order to generate a framework for quality measurements. 
Internationally, the initiative is well connected to the Stem Cell COR-
Edinates network in the US, actively exchanging protocols and discus-
sing technical developments. Together, the networks are planning to 
initiate a collaboration with journals allowing the publication of nega-
tive results from experimental datasets where this experimental data has 
been generated based on best practice study design. This will promote 
reproducibility of experiments, reduce repetition and as a result of this, 
decrease the wastage of funding resources. 
Overall, these national and international consortia have a common 
goal to deliver reproducible, robust and reliable scientific results 
through standardization and collaboration, in order to assure the value 
experimental datasets generated for basic biology and clinical 
translation. 
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